Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $114.41 USD
Change Today -2.57 / -2.20%
Volume 155.8K
CBPO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Open
$115.18
Previous Close
$116.98
Day High
$115.18
Day Low
$112.51
52 Week High
07/20/15 - $122.50
52 Week Low
08/12/14 - $44.55
Market Cap
3.0B
Average Volume 10 Days
170.7K
EPS TTM
$2.91
Shares Outstanding
26.0M
EX-Date
--
P/E TM
39.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA BIOLOGIC PRODUCTS INC (CBPO)

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; human coagulation factor VIII for treating coagulopathie; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; and human cytomegalovirus immunoglobulin. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,621 Employees
Last Reported Date: 03/4/15

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $885.4K
Chief Financial Officer
Total Annual Compensation: $366.5K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $256.8K
Corporate Vice President and General Manager ...
Total Annual Compensation: $324.5K
Corporate Vice President
Total Annual Compensation: $183.6K
Compensation as of Fiscal Year 2014.

china biologic products inc (CBPO) Key Developments

CBPO Seeks Acquisitions

China Biologic Products, Inc. (NasdaqGS:CBPO) is seeking acquisitions. CBPO intends to use net proceeds from sale of securities for general corporate purposes, which may include working capital, capital expenditures and other corporate expenses. In addition, if appropriate opportunities arise to acquire or invest in complementary products, technologies or businesses, CBPO may use a portion of the net proceeds for such acquisition or investment.

China Biologic Products, Inc. Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015

China Biologic Products, Inc. Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015 . Venue: Credit Suisse Office, Level 88, International Commerce Center, 1 Austin Road West, Kowloon, Hong Kong.

China Biologic Products, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015

China Biologic Products, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company total sales increased by 25.0% to $70.4 million from $56.3 million in the same quarter of 2014. The increase was primarily attributable to the sales increases in major plasma-based products and placenta polypeptide. Income from operations increased by 23.9% to $34.7 million from $28.0 million in the same quarter of 2014. Net income attributable to the company increased by 26.8% to $23.2 million from $18.3 million in the same quarter of 2014. Fully diluted net income per share was $0.87 in the first quarter of 2015 as compared to $0.69 in the same quarter of 2014. Non-GAAP adjusted net income attributable to the Company was $25.0 million, representing a 30.9% increase from $19.1 million in the same quarter of 2014. Non-GAAP adjusted net income per share was $0.94, compared to $0.73 in the same quarter of 2014. Net cash provided by operating activities was $16.5 million, as compared to $11.5 million for the three months ended March 31, 2014. The increase in net cash provided by operating activities was primarily due to the increase in net income for the three months ended March 31, 2015 as compared to the same period in 2014. Earnings before income tax expense was $35,271,510 against $29,290,767 a year ago. Payment for property, plant and equipment were $8,478,369 against $6,385,851 a year ago. For the full year of 2015, the company is raising its full year sales forecast. Total sales are expected to be in the range of $290 million to $295 million, which represents growth of 19% to 21% over 2014. Full year non-GAAP adjusted net income is expected to remain in the range of $95 million to $97 million, excluding the potential adverse impact of foreign currency, which represents growth of 26% to 28% over 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $114.41 USD -2.57

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY42.88 CNY -0.66
Jiangxi Boya Bio-Pharmaceutical Co Ltd CNY75.46 CNY 0.00
Northwest Biotherapeutics Inc $10.99 USD -0.87
Shanghai RAAS Blood Products Co Ltd CNY80.40 CNY +2.40
StemCells Inc $0.44 USD -0.0169
View Industry Companies
 

Industry Analysis

CBPO

Industry Average

Valuation CBPO Industry Range
Price/Earnings 40.4x
Price/Sales 11.3x
Price/Book 12.3x
Price/Cash Flow 39.6x
TEV/Sales 10.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.